Ability Pharma is a clinical stage phase 2b biopharmaceutical company focused on autophagy to treat cancer
Ability Pharma is a clinical stage phase 2b biopharmaceutical company focused on autophagy to treat cancer. The company is developing new first-in-class candidates to induce cell death selectively in cancer cells, with a pipeline including ABTL0812 currently in clinical trials for pancreatic cancer and other indications.